ArticleBMC gastroenterology2026
Gut microbiota dysbiosis and hepatic inflammation in morphine dependence and withdrawal: insights from a rat model.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOpioid dependence, particularly morphine, has been linked to gut microbiota dysbiosis and systemic inflammation, yet the interplay between gut microbial alterations and hepatic inflammatory responses remains poorly understood.
methodsFifty male Wistar rats were separated into two groups, one received escalating morphine doses (5 to 30 mg/kg over 10 days), while the other acted as a saline control. Fecal samples were collected at baseline, on days 5 and 10 of treatment, and after a 10-day withdrawal. DNA was extracted for qPCR analysis of Lactobacillus, Bifidobacterium, Clostridium, Bacteroides, and Faecalibacterium. Liver tissues were examined for inflammatory markers (TNF-α, IFN-γ, IL-6, NF-κB) using RT-qPCR after treatment and withdrawal.
resultsA significant decline in Lactobacillus (P = 0.011) and Bifidobacterium (P = 0.003) following morphine treatment, with partial recovery observed after withdrawal (P = 0.014; P = 0.0009), yet levels remained below baseline. Conversely, Clostridium levels increased significantly during treatment (P = 0.0001), persisting at elevated levels post-withdrawal (P = 0.0001). Bacteroides and Faecalibacterium also exhibited decreased abundances during morphine treatment (P > 0.05; P = 0.00009), with limited recovery thereafter (P > 0.05; P = 0.00008). Hepatic analysis revealed elevated levels of TNF-α (P < 0.0001), IL-6 (P = 0.005), and NF-κB (P = 0.41), alongside a significant reduction in IFN-γ (P < 0.001) expression in the morphine group compared to controls. After withdrawal, TNF-α (P < 0.01) and IFN-γ (P = 0.004) levels decreased, while NF-κB (P = 0.03) and IL-6 (P = 0.4(remained elevated, indicating persistent inflammatory responses.
conclusionMorphine causes lasting gut dysbiosis and liver inflammation, indicating disruption of the gut-liver axis in opioid dependence. These results emphasize morphine’s impact on gut microbiota and liver health, suggesting significant long-term effects of opioid use. Targeting microbiota modulation and anti-inflammatory approaches may offer therapeutic options for opioid-related conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.